IP Library Granted Patent US 9,119,897
Granted Patent B2
US 9,119,897 · App. 13/322,754 · Granted Sep 1, 2015

Dry powder fibrin sealant

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,119,897
App. No.
13/322,754
Granted
Sep 1, 2015
Kind
B2
Abstract

A fibrin sealant comprises a mixture of first microparticles that comprise fibrinogen, second microparticles that comprise thrombin, and additive material. The additive material may be particulate, and may be, for instance, a biocompatible, water-absorbent, material, a biocompatible, water-swellable material, a biocompatible, water-insoluble material, a polysaccharide or silica.

Claims (27)

1. A method of treating a bleeding wound, comprising: administering to a bleeding wound a powder mixture comprising a homogeneous blend of:

first microparticles having an active component consisting of fibrinogen, the first microparticles having a maximum particle size, X50, between 5 μm and 50 μm;

second microparticles having an active component consisting of thrombin, the second microparticles having a maximum particle size, X50, between 5 μm and 50 μm; and

an additive material selected to increase absorbance of fluid of the bleeding wound, the additive material in the form of discrete microparticles that are separate from the first microparticles and second microparticles and having an average particle size between 10 μm and 500 μm; and

wherein the powder mixture comprises from 30% to 80% w/w of the additive material; and stops the bleeding in less than five minutes after contact with the bleeding wound.

2. The method according to claim 1 , wherein the additive material comprises a hollow or porous material.

3. The method according to claim 1 , wherein the additive material comprises a biocompatible, water-swellable material.

4. The method according to claim 1 , wherein the additive material comprises a biocompatible, water absorbing material.

5. The method according to claim 1 , wherein the additive material comprises a biocompatible, water-insoluble material.

6. The method according to claim 1 , wherein the additive material comprises a polysaccharide.

7. The method according to claim 1 , wherein the powder mixture is contained in a pouch and administered to the bleeding wound as the pouch dissolves.

8. A dry powder mixture comprising a homogeneous blend of:

first microparticles having an active component consisting of fibrinogen, the first microparticles having a maximum particle size, X50, between 5 μm and 50 μm;

second microparticles having an active component consisting of thrombin, the second microparticles having a maximum particle size, X50, between 5 μm and 50 μm; and

an additive material selected to increase absorbance of fluid of the bleeding wound, the additive material in the form of discrete microparticles that are separate from the first microparticles and second microparticles and having an average particle size between 10 μm and 500 82 m; and

wherein the powder mixture comprises from 30% to 80% w/w of the additive material; and stops the bleeding in less than five minutes after contact with a bleeding wound.

9. The powder mixture according to claim 8 , wherein the additive material comprises a hollow or porous material.

10. The powder mixture according to claim 8 , wherein the additive material comprises a biocompatible, water-absorbing material.

11. The powder mixture according to claim 8 , wherein the additive material comprises a biocompatible, water-swellable material.

12. The powder mixture according to claim 8 , wherein said first microparticles contain 0.5 to 20% w/w fibrinogen.

13. The powder mixture according to claim 8 , wherein said second microparticles comprise 25 to 1000 IU/g thrombin.

14. The powder mixture according to claim 8 , wherein the additive material comprises a polysaccharide.

15. A pouch comprising the powder mixture according to claim 8 , wherein the pouch is configured to be applied to a wound.

16. The powder mixture according to claim 8 , wherein the powder mixture has a moisture content of no greater than 5% w/w.

17. The powder mixture according to claim 8 , wherein the additive material includes a dextran polymer.

18. The powder mixture according to claim 8 , wherein the additive material includes soluble, hollow microparticles comprising albumin.

19. The powder mixture according to claim 8 , wherein the powder mixture has a moisture content of no greater than 8% w/w.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 043596, FRAME 0259 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0324 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
NUNC PRO TUNC ASSIGNMENT Recorded Oct 6, 2017
From: PROFIBRIX B.V.
To: MALLINCKRODT PHARMA IP TRADING D.A.C.
Reel/Frame 043806/0028 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Aug 18, 2017
From: MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 043596/0259 →